Autografts, Allografts and Bone Substitutes in Lytic benign Bone Tumors and Tumour Like Lesions: A Comparative Study of Filling Defects and Healing in 90 Patients
DOI:
https://doi.org/10.12974/2313-0954.2018.05.2Keywords:
Autografts, allografts, bone substitutes, benign lytic lesions, bone, healingAbstract
Background: Extended curettage is treatment of choice for most benign lesions. To fill the defect after curettage remains a major problem particularly in children and in large cavities. We compared the results of allografts, autografts and bone substitutes in patients with benign bone tumors and tumour like conditions after curettage in view of healing of the lesion and their complications.
Material and Methods: Total 90 patients (54 males and36 females) of benign lytic bone tumors in extremities and amenable to curettage were included in this prospective study. Extended curettage was done using the sharp curettes and high-speed burr. The age of patient ranged from 6 years to 62 years. Giant cell tumor 33.3% (n=30) and aneurismal bone cyst 30% (n=27) were the most common type of tumors in our series. There were twelve patients (13.3%) of enchondroma and ten patients each (11% each) of simple bone cyst and chondroblastoma. One patient had chondromyxoid fibroma. Mean tumor volume was 29.88 cm3 (range 2.7 to 168.48). The defects were filled by either autograft, allograft or bone substitutes making the comparative groups. The mean follow up period was 46months (range 24–70).
Results: Autografts were used in 32 patients (35.6%) allografts in 28 (31.1%) and in remaining 30 cases (33.3%) bone substitutes were used. Autografts had shortest healing time with mean value of 6.77 ± 3.2 weeks (4–16 weeks) followed by bone substitutes 10.0± 2.4weeks (8-14 weeks). Allograft demonstrated maximum healing time with mean 11.25 ± 2.6weeks (range 8-16 weeks). Additional scar 100% (n=32), cosmetic deformity 6.25% (n=2), recurrence 6.25%(n=2) and infection 3.13%(n=1) were chief complications in autograft group. Serous discharge was observed in 64.3% (n=18) patients of allograft and in 23.3% (n=7) of bone substitute groups and one patient each in these two groups had infection respectively. There was one recurrence each in allograft and bone substitute groups respectively. Cost was big limiting factor for usage of bone substitutes in large cavities. Functional assessment was done by Musculoskeletal Tumor Society Rating Scale (MSTS) score while radiographic assessment of graft uptake by Irwin grading. The overall average Musculoskeletal Tumor Society (MSTS) score was 26.75 (range 24-30).
Conclusion: Autograft is the best material to fill the defect after extended curettage of benign lytic lesions of bone. Bone substitutes and allografts are the options if autograft not available like in children. We observed that in small cavities bone substitutes can be an effective alternative and in large cavities it is better to use either allograft alone or a combination of autograft.
References
Fletcher CDM, Bridge JA, Hogendooren P and Mertens F, editors. World Health Organization, Classification of Tumors. Pathology and genetics of tumors of soft tissue and bone. Lyon IARC Press: 2013.
Ahn JI and Park JS. Pathological fractures secondary to unicameral bone cysts. Int Orthop 1994; 18: 20-22. https://doi.org/10.1007/BF00180173
Arata MA, Peterson HA and Dahlin DC. Pathological fractures through non-ossifying fibromas: review of the Mayo Clinic experience. J Bone Joint Surg Am 1981; 63: 980-8. https://doi.org/10.2106/00004623-198163060-00016
Toy PC and Heck RKJr. General principles of tumors. In: Canale ST, Beaty JH, editors. Campbell's operative orthopaedics.12th ed. Philadelphia: Mosby Elsevier 2013; 788.
McGarry SV. Extended curettage for benign bone lesions. Techniques in Orthopaedics 2007; 22: 121-6. https://doi.org/10.1097/BTO.0b013e31811f35d4
Hirn M, de Silva U, Sidharthan S, Grimer RJ, Abudu A, et al. Bone defects following curettage do not necessarily need augmentation. Acta Orthop 2009; 80: 4-8. https://doi.org/10.1080/17453670902804505
Yanagawa T, Watanabe H, Shinozaki T and Takagishi K. Curettage of benign bone tumors without grafts gives sufficient bone strength. Acta Orthop 2009; 80: 9-13. https://doi.org/10.1080/17453670902804604
Puri A and Agarwal M. Treatment of giant cell tumor of bone: current concepts. Indian J Orthop2007; 41: 101-8. https://doi.org/10.4103/0019-5413.32039
Enneking WF, Dunham W, Gebhardt MC, Malawar M and Pritchard DJ. A system for the functional evaluation of reconstructive procedures after surgical treatment of tumors of the musculoskeletal system. Clin Orthop Relat Res 1993; 286: 241-6. https://doi.org/10.1097/00003086-199301000-00035
Irwin RB, Berhard M and Biddinger A. Coralline hydroxyapatite as bone substitute in orthopaedic oncology. Am J Orthop 2001; 30: 544-50.
Kundu ZS, Gogna P, Singla R, Sangwan SS, Kamboj P and Goyal S. Joint salvage using sandwich technique for giant cell tumors around knee. J Knee Surg 2015; 28: 157-64. https://doi.org/10.1055/s-0034-1373738
Kundu ZS, Gupta V, Sangwan SS, Rana P. Curettage of benign bone tumors and tumor-like lesions. A retrospective analysis. Indian J Orthop 2013; 47: 295-301. https://doi.org/10.4103/0019-5413.111507
Glancy GL, Brugioni DJ, Eilert RE and Chang FM. Autograft versus allograft for benign lesions in children. Clin Orthop Relat Res 1991; 262: 28-33. https://doi.org/10.1097/00003086-199101000-00005
Yang Y, Niu X, Zhang Q, Hao L, Ding Y and Xu H. A comparative study of calcium sulfate artificial bone graft versus allograft in reconstruction of bobe defect after tumor curettage. Chin Med J 2014; 127: 3092-7.
Yercan H, Ozalp T, Coskunol E and Ozdemir O. Long term results of autograft and allograft applications in hand enchondromas. Acta Orthop Traumatol Turc 2004; 38: 337-42.
Schindler OS, Cannon SR, Briggs TW and Blunn GW. Composite ceramic bone graft substitute containing calcium sulphate and hydroxyapatite (HA) in the treatment of large expansive osteolytic benign bone tumors. J Orthop Surg 2008; 16: 66-74. https://doi.org/10.1177/230949900801600116
Sethi A, Agarwal K, Sethi S, Kumar S, Marya SKS and Tuli SM. Allograft in treatment of benign cystic lesions of bone. Arch Orthop Tauma Surgery 1993; 112: 167-170. https://doi.org/10.1007/BF00662282
Shih HN, Su JY, Hsu KY and Hsu RW. Allogenic cortical strut for benign lesions of the humerus in adolescents. J Pediatr Orthop 1997; 17: 433-6. https://doi.org/10.1097/01241398-199707000-00003
Gupta AK, Keshav K and Kumar P. Decalcified allograft in repair of lytic lesions of bone: a study to evolve bone bank in developing countries. Indian J Orthop 2016; 50: 427-33. https://doi.org/10.4103/0019-5413.185609
